share_log

Apollomics Shares Are Trading Lower After the Company Announced Its Phase 3 Bridging Trial of Uproleselan in China Did Not Demonstrate a Favorable Benefit.

Apollomics Shares Are Trading Lower After the Company Announced Its Phase 3 Bridging Trial of Uproleselan in China Did Not Demonstrate a Favorable Benefit.

Apollomics的股票在公司宣佈其在中國的Uproleselan III期橋接試驗未能顯示出有利的益處後,交易下跌。
Benzinga ·  12/20 21:44

Apollomics Shares Are Trading Lower After the Company Announced Its Phase 3 Bridging Trial of Uproleselan in China Did Not Demonstrate a Favorable Benefit.

Apollomics宣佈其在中國進行的Uproleselan的第三階段過渡試驗並未顯示出有利的收益,此後,該公司股價走低。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論